Non Melanoma Skin Cancer Market Report 2024 (Global Edition)

Global Non Melanoma Skin Cancer Market Report 2024 Market Size Split by Treatment Type Outlook: (Radiation Therapy, Chemotherapy, Photodynamic Therapy), by Indication Outlook: (Basal Cell Carcinoma, S...

Non Melanoma Skin Cancer Market Report Description

We have various report editions of Non Melanoma Skin Cancer Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Non Melanoma Skin Cancer Market Insights Video

Competitive Landscape of the Non Melanoma Skin Cancer Market

The companies that merged are focusing on non-invasive therapies such as photodynamic therapy and cryotherapy. The market is highly competitive as a result of continual R&D initiatives, new product launches, and strategic alliances. Regulatory approvals for novel therapies, as well as increased investment in cancer treatment technology, are changing the market's competitive dynamics.

In February 2024, Almirall has formed a strategic partnership with Microsoft to drive dermatologic innovation and digital transformation. The three-year collaboration will use generative artificial intelligence (genAI) and advanced analytics to improve drug discovery and development, with the goal of bringing novel treatments to medical dermatology. (Source: https://www.pharmaceutical-technology.com/news/almirall-microsoft-dermatological-drug/ ) In February 2024, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection, for patients in the United States. Tecentriq Hybreza can be given subcutaneously in around seven minutes, whereas normal Tecentriq (atezolizumab) infusion takes 30-60 minutes.2 It will be offered for all IV indications of Tecentriq approved for adults in the United States, including specific types of lung, liver, skin, and soft tissue cancer.3 (Source: https://www.globenewswire.com/news-release/2024/09/13/2945689/0/en/FDA-approves-Roche-s-Tecentriq-Hybreza-the-first-and-only-subcutaneous-anti-PD-L-1-cancer-immunotherapy.html ) In September 2024, Eli Lilly and Company (NYSE: LLY) and EVA Pharma said today that the firms have entered into a deal to provide access to baricitinib to an estimated 20,000 patients in 49 low- to middle-income countries in Africa by 2030. Baricitinib, discovered by Incyte and licensed to Lilly, is used to treat rheumatoid arthritis, alopecia areata, atopic dermatitis, and covid-19. (Source: https://www.prnewswire.com/news-releases/lilly-and-eva-pharma-collaborate-to-expand-access-to-baricitinib-in-low--to-middle-income-countries-302237321.html )

Top Companies Market Share in Non Melanoma Skin Cancer Industry: (In no particular order of Rank)

• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Almirall
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• Merck & Co.
• Inc.
• Novartis AG
• Eli Lilly and Company
• Sun Pharmaceutical Industries Ltd.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Non Melanoma Skin Cancer Market

Which Region Dominates the Non Melanoma Skin Cancer Market in 2024?

According to Cognitive Market Research, North America currently dominates the Non Melanoma Skin Cancers market, and the region is expected to have significant growth during the projected period. It is due to the higher occurrence of skin cancer in the United States, as well as the increased penetration of cancer medications in the country. In addition, prominent market players' preference for launching innovative skin cancer treatments is expected to have a beneficial impact on regional market growth.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). The regulatory approvals for these skin cancer medications in Asia Pacific, together with the availability of a huge and underserved market in the region's emerging countries, are expected to boost the skin cancer treatment market growth in Asia Pacific.

The current report Scope analyzes Non Melanoma Skin Cancer Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Non Melanoma Skin Cancer

According to Cognitive Market Research, the global Non Melanoma Skin Cancer market size was estimated at USD 5215.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 2086.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Non Melanoma Skin Cancer market with a market size of USD 1645.92 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. The U.S. growing elderly population is more prone to non-melanoma skin cancer (NMSC) due to prolonged UV exposure over time.
• The Canada Non Melanoma Skin Cancer market had a market share of USD 250.33 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Canada’s rising awareness among the population.
• The Mexico Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 189.83 million in 2024.

Europe Non Melanoma Skin Cancer

According to Cognitive Market Research, the global Non Melanoma Skin Cancer market size was estimated at USD 5215.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 1564.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.

• The United Kingdom Non Melanoma Skin Cancer market had a market share of USD 262.85 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. In the UK, public health campaigns encourage regular skin checks and awareness about skin cancer.
• The France Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 143.94 million in 2024.
• According to Cognitive Market Research, the German Non Melanoma Skin Cancer market size was valued at USD 309.78 million in 2024 and is projected to grow at a CAGR of 4.7% during the forecast period. Germany's aging population drives a higher incidence of NMSC due to cumulative sun exposure over decades.
• The Italy Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 3.9% during the forecast period, with a market size of USD 134.55 million in 2024.
• The Russia Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD 242.51 million in 2024.
• The Spain Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD 128.29 million in 2024
• The Luxembourg Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 48.50 million in 2024.
• The Portugal Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 4.3% during the forecast period, with a market size of USD 32.86 million in 2024.
• The Greece Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 18.77 million in 2024.
• The Rest of Europe's Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD 242.51 million in 2024.

Asia Pacific Non Melanoma Skin Cancer

According to Cognitive Market Research, the global Non Melanoma Skin Cancer market size was estimated at USD 5215.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 1199.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Non Melanoma Skin Cancer market size was valued at USD 539.77 million in 2024 and is projected to grow at a CAGR of 7.5% during the forecast period. In China, increasing UV exposure and skin cancer risks..
• The Japan Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 165.53 million in 2024.
• The India Non Melanoma Skin Cancer market had a market share of USD 143.94 million in 2024 and is projected to grow at a CAGR of 9.8% during the forecast period. India's expansion of healthcare facilities.
• The South Korean Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 7.1% during the forecast period, with a market size of USD 119.95 million in 2024.
• The Australian Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 62.37 million in 2024.
• The South East Asia Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD 82.77 million in 2024.
• The Rest of Asia Pacific Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 7.8% during the forecast period, with a market size of USD 85.16 million in 2024.

South America Non Melanoma Skin Cancer

According to Cognitive Market Research, the global Non Melanoma Skin Cancer market size was estimated at USD 5215.2 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 260.76 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Non Melanoma Skin Cancer market size was valued at USD 111.61 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. Non Melanoma Skin Cancers flourished in Brazil due to increasing demand for packaged food and beverages.
• Argentina's Non Melanoma Skin Cancer market had a market share of USD 43.81 million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period. Argentina's rising personal disposable income.
• Colombia Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 23.21 million in 2024.
• Peru Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 21.38 million in 2024.
• Chile Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 18.77 million in 2024.
• The Rest of Latin America's Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 41.98 million in 2024.

Middle East and Africa Non Melanoma Skin Cancer

According to Cognitive Market Research, the global Non Melanoma Skin Cancer market size was estimated at USD 5215.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 104.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

• The GCC Countries Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 44.64 million in 2024. The GCC is attracting patients from surrounding regions for advanced cancer treatments, including skin cancer.
• The Egypt Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 10.95 million in 2024.
• The South Africa Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 16.48 million in 2024. South Africa has one of the highest UV exposure rates in the world, significantly increasing the risk of NMSC.
• The Turkey Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 8.97 million in 2024.
• The Nigeria Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 10.95 million in 2024.
• The Rest of the MEA Non Melanoma Skin Cancer market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 12.31 million in 2024.

Non Melanoma Skin Cancer Market Analysis

 

Non Melanoma Skin Cancer Market Treatment Type Segment Analysis

According to Cognitive Market Research, Chemotherapy is likely to dominate the Non Melanoma Skin Cancer Market over the forecast period. The demand for chemotherapy in the non-melanoma skin cancer market is increasing, particularly for advanced cases of squamous cell carcinoma (SCC). Chemotherapy is typically used when cancer has spread and cannot be treated with surgery or radiation. Chemotherapeutic medicines are systemic treatments that help shrink tumors and limit metastasis. They are frequently used in conjunction with other therapy.

The Radiation Therapy is the fastest-growing segment in the Non Melanoma Skin Cancer Market. Radiation therapy is an essential therapeutic option for non-melanoma skin cancer, especially for individuals who are unable to undergo surgery or who have recurring tumors. This therapy is becoming increasingly popular since it provides a non-invasive method of targeting cancer cells, particularly in delicate areas such as the face and neck. Intensity-modulated radiation therapy (IMRT) and brachytherapy are two technological developments that have enhanced treatment precision while reducing side effects.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Non Melanoma Skin Cancer Industry. Request a Free Sample PDF!

 

Non Melanoma Skin Cancer Market Indication Segment Analysis

According to Cognitive Market Research, the Basal Cell Carcinoma segment holds the largest share of the market. Basal cell carcinoma (BCC) is the most common type of non-melanoma skin cancer, accounting for a sizable market share. BCC is typically slow-growing and rarely spreads, making it easily treated when identified early. Localized BCC is commonly treated with surgical excision, cryotherapy, and topical therapies.

 

 In the Non Melanoma Skin Cancer Market, the Squamous Cell Carcinoma has been expanding at a rapid pace. Squamous cell carcinoma (SCC), the second most frequent kind of non-melanoma skin cancer, creates a strong demand for better therapeutic alternatives. SCC is more likely to spread than basal cell carcinoma, making early intervention critical. For severe cases, treatment options include surgery, radiation, and chemotherapy. Immunotherapies are also being investigated for metastatic or recurrent SCC.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Non Melanoma Skin Cancer End-use Outlook: Segment Analysis

Non Melanoma Skin Cancer Market End-use Segment Analysis

According to Cognitive Market Research, the Specialty Clinics segment dominates the market. Dermatology and oncology specialty clinics are seeing a rise in demand for non-melanoma skin cancer treatments. These clinics appeal to patients who desire specialist care by providing innovative and tailored treatments such as Mohs surgery, photodynamic therapy, and targeted therapies. With the increased incidence of basal cell carcinoma and squamous cell carcinoma, specialist clinics offer expertise and targeted treatment choices that ordinary hospitals may not.
Hospitals are projected to be the fastest-growing segment in the Non Melanoma Skin Cancer market. Hospitals play an important role in the treatment of non-melanoma skin cancer, especially for advanced cases that require extensive care. The demand for hospital-based services stems from the necessity for specialized facilities that combine surgery, radiation therapy, and chemotherapy under one roof. Large hospitals frequently treat complex or aggressive instances of basal cell carcinoma and squamous cell carcinoma, including those with metastases.
 

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion